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Abstract
Background: Endothelial-mesenchymal transition (EndoMT) is a major source of myofibroblast formation in kidney
fibrosis. Our previous study showed a profibrotic role for matrix metalloproteinase 9 (MMP-9) in kidney fibrosis via
induction of epithelial-mesenchymal transition (EMT). Inhibition of MMP-9 activity reduced kidney fibrosis in murine
unilateral ureteral obstruction. This study investigated whether MMP-9 also plays a role in EndoMT in human
glomerular endothelial cells.
Results: TGF-β1 (10 or 20 ng/ml) induced EndoMT in HKGECs as shown by morphological changes. In addition, VE-
cadherin and CD31 were significantly downregulated, whereas α-SMA, vimentin, and N-cadherin were upregulated.
RT-PCR revealed that Snail, a known inducer of EMT, was upregulated. The MMP inhibitor GM6001 abrogated TGF-
β1-induced EndoMT. Zymography indicated that MMP-9 was also upregulated in TGF-β1-treated HKGECs.
Recombinant MMP-9 (2 μg/ml) induced EndoMT in HKGECs via Notch signaling, as evidenced by increased
formation of the Notch intracellular domain (NICD) and decreased Notch 1. Inhibition of MMP-9 activity by its
inhibitor showed a dose-dependent response in preventing TGF-β1-induced α-SMA and NICD in HKGECs, whereas
inhibition of Notch signaling by γ-secretase inhibitor (GSI) blocked rMMP-9-induced EndoMT.
Conclusions: Taken together, our results demonstrate that MMP-9 plays an important role in TGF-β1-induced
EndoMT via upregulation of Notch signaling in HKGECs.
Keywords: Matrix metalloproteinase 9, Endothelial-mesenchymal transition, Human glomerular endothelial cells,
TGF-β1, Notch
Background
Kidney fibrosis is an inevitable consequence of a wide
variety of progressive chronic kidney diseases (CKD) that
progress to end-stage kidney failure, a devastating
disorder that requires kidney replacement therapies such
as dialysis or kidney transplantation. Kidney fibrosis is
characterized by tubular atrophy/dilation, interstitial
leukocyte infiltration, fibroblast accumulation, and in-
creased interstitial matrix deposition [1, 2]. Although
different cells are involved in kidney fibrosis, fibroblasts
or myofibroblasts are considered to play a pivotal role
[3]. However, the cellular origins of myofibroblasts are di-
verse. Resident fibroblasts [4], fibrocytes from bone mar-
row [4, 5], pericytes and perivascular fibroblasts [5, 6],
tubular epithelial cells [4, 5, 7], podocytes [8] and endothe-
lial cells [7, 9] have been identified as contributing to the
myofibroblast population.
Endothelial-mesenchymal transition (EndoMT) is process
similar to that of epithelial-mesenchymal transition (EMT).
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During EndoMT, endothelial cell markers are downregu-
lated whereas mesenchymal markers are upregulated.
EndoMT is involved in organ development and various
types of fibrosis. For example, EndoMT contributes to
cardiac fibrosis [10–12], pulmonary fibrosis [10, 13], cor-
neal fibrosis [14], radiation-induced pelvic disease [15] and
inflammatory bowel disease-associated fibrosis [16].
EndoMT was also found in the early development of kidney
interstitial fibrosis in the streptozocin (STZ)-induced dia-
betic nephropathy (DN) model [17, 18]. In addition,
EndoMT also contributes to carcinoma-associated fibro-
blasts [19], atherogenesis, inflammation and hypertension
[20, 21]. LeBleu et al. showed that ~10 % of the interstitial
myofibroblasts co-stained with markers of endothelial cells
and activated fibroblasts in unilateral ureteral obstruction
(UUO) mice [7]. Zeisberg and colleagues [9] have demon-
strated a role for EndoMT in several models of kidney dis-
ease. These studies demonstrated that activated fibroblasts
co-express the endothelial marker CD31 as well as fibro-
blast markers such as fibroblast specific protein-1 (FSP-1)
and α-smooth muscle actin (α-SMA). To demonstrate the
presence of EndoMT-derived fibroblasts, these authors also
used lineage tagged transgenic mice to trace endothelial
lineage. Taken together, these findings suggest EndoMT
plays a critical role in myofibroblast formation. EndoMT
inhibition or reversal might be a potential target for treat-
ment and prevention of kidney fibrosis.
Notch family is involved in podocyte and kidney tubu-
lar cell differentiation [22]. Abnormal Notch pathway ac-
tivation can lead to glomerulonephritis (GN) and focal
segmental glomerulosclerosis (FSGS) [23, 24]. Notch sig-
naling is typically activated upon binding of ligands
(such as Dll1, Dll3, Dll4, Jag1, and Jag2) with Notch 1–4
receptors. Then intramembrane proteolysis such as ecto-
domain shedding of both the ligand and the receptor, re-
leasing the intracellular domains (ICD) of the ligand and
receptor, thereby allowing Notch ICD (NICD) nuclear
translocation to regulate gene expression.
We previously found that matrix metalloproteinase 9
(MMP-9) is capable of inducing tubular cell EMT and
contribute to tubulointerstitial fibrosis [25, 26]. Although
endothelial cells are capable of expressing MMP-9 [18],
whether MMP-9 plays a role in EndoMT was unknown.
In the current study, we defined a role for MMP-9 in
EndoMT via Notch signaling.
Methods
Cell culture and treatment
Human kidney glomerular endothelial cells (HKGECs)
were cultured in endothelial cell media (ScienCell; Carls-
bad, CA, USA) containing vascular endothelial growth
factor (VEGF; Sigma-Aldrich; St. Louis, MO, USA; 2.5–
5 μg/ml) in basal medium (ScienCell), 5 % fetal bovine
serum (FBS; ScienCell), 1 % endothelial cell growth
supplement (ECGS; ScienCell) and 1 % penicillin/
streptomycin (P/S; ScienCell). Cells were maintained at
37 °C with 5 % CO2. For treatment, HKGECs were cul-
tured for 24 h at low density in flasks or plates pre-
coated with fibronectin and washed in PBS. Cells
were treated with TGF-β1 (10 ng/ml or 20 ng/ml;
Sigma-Aldrich) alone, TGF-β1 plus 10 μM GM6001
(Calbiochem; Darmstadt, Germany), TGF-β1 plus the
MMP-9 inhibitor I (Merck Chemicals; Darmstadt,
Germany) at different dosages (0.05 nmol/ml, 0.25 nmol/
ml, and 0.5 nmol/ml), recombinant MMP-9 (rMMP-9;
2 μg/ml; Biomol International; Plymouth Meeting, PA,
USA), or rMMP-9 (2 μg/ml) plus the gamma secretase in-
hibitor (GSI; 5–10 μM; Merck Millipore; Billerica, MA,
USA). Our study does not require any human or animal
ethics approval.
Immunofluorescence analysis
For indirect immunofluorescence, HKGECs were cultured
on glass coverslips, washed twice in PBS, fixed with abso-
lute methanol for ten minutes at −20 °C, and blocked for
1 h with 2 % BSA (Sigma) at room temperature. Cells
were then incubated for 1 h at room temperature with pri-
mary antibodies against endothelial markers rabbit poly-
clonal anti-VE-cadherin (1:200; Alexis Biochemicals;
Farmingdale, NY, USA), mouse monoclonal anti-CD31
(1:100; Cell Signaling Technology; Boston, MA, USA) and
mesenchymal markers mouse monoclonal anti-α-SMA
(1:200; Sigma Chemical Co), rabbit monoclonal anti-
vimentin (1:200; Cell Signaling Technology) and rabbit
monoclonal anti-N-cadherin (1:100, BD Bioscience; San
Jose, CA, USA) in 2 % BSA. The following secondary anti-
bodies were used: goat anti-mouse IgG2a/2b phycoeryth-
rin (PE)-conjugated antibody (1:400; Invitrogen; Carlsbad,
CA, USA) for CD31, α-SMA and goat anti-rabbit IgG2a/
2b FITC-conjugated antibody (1:400; Invitrogen) for VE-
cadherin, vimentin and N-cadherin. Cells were washed
twice with PBS, counterstained with DAPI for 5 min, and
washed twice with PBS. Samples were mounted using
fluorescence mounting media. For negative isotype con-
trols staining, rat IgG2a κ purified (eBioscience; San
Diego, CA, USA) was used for VE-cadherin, vimentin and
N-cadherin mouse IgG2a κ (Biolegend; San Diego, CA,
USA) was used for CD31 and α-SMA, and their corre-
sponding secondary antibodies were applied.
RNA extraction, purification, and quantitation
Total RNA was extracted from cultured cells using
350 μl of RLT buffer and homogenized by shredding
through a 0.5 ml insulin syringe 5 times. Extracted
RNA was purified using RNeasy Mini Kit (Qiagen;
Hilden, Germany) following the manufacturer’s in-
struction and resuspended in 30 μl of RNAse-free
water. The yield and purity of RNA was measured
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spectrophotometrically by absorption at 260 nm
(A260) and 280 nm (A280) using a Beckman-Coulter
DU800 spectrophotometer (CA, USA).
Real-time RT-PCR analysis
cDNAs were synthesized using 200 ng of extracted RNA
in 20 μl reaction buffer by reverse transcription using
Fig. 1 TGF-β1 induces EndoMT in HKGECs. a Morphological changes in HKGECs induced by TGF-β1 (10 ng/ml) were examined using phase contrast
microscopy. b Indirect immunofluorescence staining and co-localization of VE-cadherin and α-SMA were performed in HKGECs cultured in
Endothelial Cell Medium with TGF-β1 (10 ng/ml). c Morphological changes in HKGECs induced by TGF-β1 (20 ng/ml) were examined
using phase contrast microscopy. Cells were counterstained with DAPI to visualize nuclei (blue). d Indirect immunofluorescence staining
and co-localization of VE-cadherin and α-SMA were performed in HKGECs cultured in Endothelial Cell Medium with TGF-β1 (20 ng/ml).
e Indirect immunofluorescence staining of CD31, vimentin, and N-cadherin was performed in HKGECs cultured in Endothelial Cell Medium
with TGF-β1 (10 ng/ml). f Respective western blot analysis and quantitation of CD31, α-SMA, VE-cadherin, N-cadherin, and vimentin in HKGECs
treated with TGF-β1 (10 ng/ml). β-actin was used as a loading control. g Snail mRNA expression from HKGECs cultured in Endothelial Cell Medium with
TGF-β1 (10 ng/ml) was quantified using real-time PCR. Gene expression levels were normalized to human GADPH mRNA. Original magnification × 200.
Data are expressed as mean ± SEM with n≥ 3 for each experimental group, *P < 0.05, **P< 0.01. Morphological and immunofluorescent are representa-
tive of experiments repeated 3 times
Zhao et al. BMC Cell Biology  (2016) 17:21 Page 3 of 11
SuperscriptTM First Strand Synthesis System (Invitrogen)
and random hexamer primers at 50 °C for 50 min. De-
signed primers and established primers from published
papers were used for Real-time RT-PCR. The sequences
of hes-1 primers used for this analysis are as follows: for-
ward: 5′-GAC AGC ATC TGA GCA CAG AAA TG-3′
and reverse: 5′- GTC ATG GCA TTG ATC TGG GTC
AT-3′ [27]. Housekeeping gene β-actin was used as the
internal control. For Real-time RT-PCR, PCR mixture
contained 0.5 μl of cDNA and 10 ρmol/μl of each primer
in a 20 μl final volume of SYBR mastermix (Invitrogen).
Amplification was performed using the Rotogene-6000
Real-Time cycler thermos.
Western blot analysis
Equal volumes or quantities of protein were loaded in
12-well NuPAGE 4–15 % Bis-Tris gels (Bio-Rad;
Hercules, CA, USA) and electrophoresed under reducing
conditions. After electrophoresis, proteins were trans-
ferred for 2 h to PVDF membranes using a Mini Trans-
Blot Electrophoretic Transfer Cell apparatus (Bio-Rad).
For immunodetection, membranes were blocked over-
night at 4 °C in 5 % skim milk and incubated for 2 h at
room temperature with the primary antibody against
mouse monoclonal anti-α-SMA (1:300, Sigma Chemical
Co.), rabbit polyclonal anti-VE-cadherin (1:1000; Alexis
Biochemicals), mouse monoclonal anti-CD31 (1:1000;
Fig. 2 GM6001 inhibits TGF-β1-induced EndoMT in HKGECs. a Morphological changes in HKGECs induced by TGF-β1 (10 ng/ml) in the presence
or absence of GM6001 were examined using phase contrast microscopy. b Indirect immunofluorescence staining of VE-cadherin and α-SMA were
performed in HKGECs cultured in Endothelial Cell Medium with TGF-β1 (10 ng/ml). c Respective western blot analysis and quantitation of CD31,
VE-cadherin and α-SMA were performed in HKGECs treated with TGF-β1 (10 ng/ml) in the presence or absence of GM6001. β-actin was used as a
loading control. Original magnification × 200. Image are representative and data are expressed as mean ± SEM with n≥ 3 for each experimental
group, *P < 0.05, **P < 0.01
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Cell Signaling Technology), mouse polyclonal anti-NICD
(1;1000; Merck Millipore, Cat. # 07–1232) [28], β-actin
(1:3000, Sigma), rabbit monoclonal anti-Notch1 (1:1000;
Cell Signaling Technology), rabbit monoclonal anti-
vimentin (1:1000; Cell Signaling Technology), rabbit
monoclonal anti-N-cadherin (1:500, BD BioSciences),
rabbit polyclonal anti-Hes-1 (1:500, Abcam; Cambridge,
UK) and rabbit polyclonal anti-Hey-1 (1:500, Abcam)
prepared in blocking buffer. Membranes were washed
three times (10 min per wash on a rocking platform)
and incubated for 1 h with their respective horseradish
peroxidase (HRP)-conjugated secondary antibodies; goat
anti mouse HRP and goat anti-rabbit HRP (1:5000; Cell
Signaling Technology) prepared in blocking buffer.
Membranes were again washed three times (10 min per
wash on a rocking platform). Bands were visualized
using an enhanced chemiluminescence detection kit.
Zymography
MMP-9 activity in medium derived from TGF-β treated
HKGECs was determined by gelatin zymography. Briefly,
medium was mixed with Tris-Glycine SDS Native Sam-
ple Buffer (1:1; Invitrogen) and electrophoresed through
10 % Novex Zymogram Gelatin Gels (Invitrogen) with
Tris-Glycine SDS Running Buffer (Invitrogen) under
constant voltage of 125 V for 120 min. After electro-
phoresis, gels was incubated in Zymogram Renaturing
Buffer (Invitrogen) for 30 min at room temperature with
gentle agitation and washed with developing buffer
(Invitrogen) for 30 min. The gel was further incubated
for 24 h in fresh developing buffer at 37 °C. After devel-
oping, the gel was stained with 0.5 % (w/v) Coomassie
Blue R-250 (Bio-Rad) in 50 % (v/v) methanol, 10 % (v/v)
acetic acid for 30 min at room temperature, and
destained as described previously [25]. Gelatinolytic ac-
tivity of MMP-9 was visualized as a clear band on a blue
background. Band intensity was quantified by densitom-
etry using ImageJ software. Briefly, zymogram gels were
scanned using Kodak gel logic 100 imaging system and
processed into gray scale. Gray scale images were quan-
tified densitometrically by the measurement of the mean
intensity of positive band multiplied by its corresponding
area. The optical band intensity was then corrected by
subtracting background intensity of equal area.
Statistical analysis
Results from at least three independent experiments are
expressed as mean ± SEM. Statistical significance was
evaluated using two-tail t-test for comparison between
two groups, whereas the one way analysis of variance
(ANOVA) was used for comparison of multiple groups.
P < 0.05 was considered significant.
Results
TGF-β1 induces EndoMT in HKGECs
To determine whether TGF-β induces EndoMT,
HKGECs were treated in the presence or absence of
TGF-β1. HKGECs exhibited morphological changes typ-
ical of EndoMT, as shown by phenotypic transformation
from an endothelial cobblestone shape to fibroblastic
spindle-shaped morphology by day 2 (Fig. 1a) and in-
creasing numbers of fibroblasts evident on days 4 to 6
(Fig. 1a). Cells cultured in the absence of TGF-β showed
fewer morphological changes. The transition from an
Fig. 3 Evaluation of MMP-9 activity. a MMP-9 activity in response to
TGF-β was examined using gelatin zymography. Relative activity was
compared to control (without TGF-β treatment). b CD31, VE-
cadherin, and α-SMA expression in HKGECs treated with TGF-β1
(10 ng/ml) and various dosages of the MMP-9 inhibitor (0.05, 0.25,
and 0.5 nmol/ml) were evaluated using western blot analysis. β-actin
was used as a loading control. c MMP-9 activity was determined
using gelatin zymography. Relative activity was compared to control
(without TGF-β1 treatment). Data are expressed as mean ± SEM with
n≥ 3 for each experimental group, *P < 0.05, **P < 0.01, ***P < 0.001
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Fig. 4 (See legend on next page.)
Zhao et al. BMC Cell Biology  (2016) 17:21 Page 6 of 11
endothelial to mesenchymal phenotype was confirmed
using immunofluorescent staining. Endothelial cells treated
with TGF-β1 (10 and 20 ng/ml) lost VE-cadherin expres-
sion and acquired α-SMA expression (Fig. 1b and c). When
treated with higher concentration of TGF-β1 (20 ng/ml),
morphological changes in HKGECs typical of EndoMT was
also induced (Fig. 1c). Immunofluorescence staining
showed decreased expression of VE-cadherin and increased
expression of α-SMA, particularly in samples that were
treated with TGF-β1 for 6 days (Fig. 1d). However, 20 ng/
ml TGF-β1 could not induce EndoMT in a shorter time.
There were no notable differences in α-SMA-stained cells
at days 2 and 4 compared to 10 ng/ml TGF-β1 treatments.
These results suggest that TGF-β1 is capable of inducing
EndoMT in HKGECs in 6 days. To further confirm
TGF-β induction of EndoMT in HKGECs, cells were
stained with the endothelial marker CD31 and the
mesenchymal markers vimentin and N-cadherin. The
transition from an endothelial phenotype to a mesen-
chymal phenotype was confirmed using immunofluor-
escent staining. Upon TGF-β1 treatment, endothelial
cells lost CD31 expression and acquired vimentin and
N-cadherin expression (Fig. 1e). Immunofluorescent
staining specificity was confirmed by negative control
staining for each isotype control antibody. Consistent
with the immunofluorescence staining results, western
blot analysis revealed decreased levels of the endothe-
lial markers VE-cadherin and CD31 in HKGECs
treated with TGF-β1. However, there was increased
expression of the mesenchymal markers α-SMA,
vimentin, and N-cadherin (Fig. 1f ). EndoMT was also
confirmed by real-time PCR analysis. We observed
upregulation of the transcription factor Snail mRNA
in HKGECs treated with TGF-β1 compared to control
HKGECs (Fig. 1g). Taken together, these results dem-
onstrate that TGF-β1 induces EndoMT in HKGECs.
The MMP inhibitor GM6001 inhibits TGF-β1-induced
EndoMT in HKGECs
To determine whether MMPs contribute to TGF-β1-
induced EndoMT, HKGECs were treated with the
broad-spectrum MMP inhibitor GM6001. After treat-
ment for 6 days, we found that EndoMT induced by
10 ng/ml TGF-β1 was abrogated by GM6001; the
(See figure on previous page.)
Fig. 4 rMMP-9 induces EndoMT in HKGECs. a rMMP-9-induced morphological changes in HKGECs were examined using phase contrast microscopy.
b Indirect immunofluorescence staining of CD31, α-SMA, VE-cadherin, and vimentin was performed in HKGECs cultured in Endothelial Cell Medium in
the presence or absence of rMMP-9 (2 μg/ml). c Western blot analysis of CD31, VE-cadherin and α-SMA in HKGECs treated or not with rMMP-9 (2 μg/
ml). β-actin was used as a loading control. Original magnification × 200. Data are expressed as mean ± SEM with n≥ 3 for each experimental group,
*P < 0.05, **P< 0.01
Fig. 5 The Notch pathway is activated in TGF-β1-induced EndoMT. a Respective western blot analysis and quantitation of Notch-1 and NICD
expression in TGF-β1 (10 ng/ml) induced EndoMT in HKGECs six days after treatment. β-actin was used as a loading control. b qPCR analysis of Hes-1
expression in TGF-β1-induced EndoMT in HKGECs. Data are expressed as mean ± SEM with n≥ 3 for each experimental group, *P < 0.05, **P < 0.01
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majority of HKGECs maintained typical endothelial
cobblestone morphology with few cells exhibiting fibro-
blastic spindle-shape morphology (Fig. 2a). Consistent
with the cellular morphology, immunofluorescence
(Fig. 2b) and western blot analysis (Fig. 2c) indicated
that GM6001 abrogated the TGF-β1-induced decrease in
CD31 and VE-cadherin expression and increase in α-
SMA expression. Collectively, these results suggest that
MMPs are involved in TGF-β1-induced EndoMT in
HKGECs.
MMP-9 is involved in TGF-β1-induced EndoMT in HKGECs
Gelatin zymography showed that MMP-9 activity in-
creased significantly within 4 days in the presence of
conditioned media with 10 ng/ml or 20 ng/ml TGF-β1
(Fig. 3a). After the cells had been cultured for 6 days,
MMP-9 activity in the media was upregulated in both
the presence of 10 ng/ml or 20 ng/ml TGF-β1. No
MMP-2 expression was detected in the media (Fig. 3a).
To further examine whether MMP-9 is involved in
EndoMT, HKGECs were treated with TGF-β1 in pres-
ence of MMP-9 inhibitor. Our results demonstrated that
the MMP-9 inhibitor reduced α-SMA expression in the
TGF-β1-treated samples. In addition, when different
dosages of MMP-9 inhibitor were used, the reduction in
α-SMA and recovery of VE-cadherin expression was
dose dependent (Fig. 3b). To confirm that the MMP-9
inhibitor was functional, zymography was performed to
evaluate MMP-9 and MMP-2 activity. The results
showed that the MMP-9 inhibitor successfully inhibited
MMP-9 activity (Fig. 3c).
rMMP-9 induces EndoMT in HKGECs
To determine whether MMP-9 contributes to EndoMT,
subconfluent HKGECs were treated with rMMP-9
(2 μg/ml). rMMP-9 induced HKGEC phenotypic trans-
formation from the endothelial cobblestone shape to the
fibroblastic spindle-shaped morphology within 6 days of
treatment (Fig. 4a). The transition of an endothelial to
mesenchymal phenotype was confirmed by immuno-
fluorescence (Fig. 4b). Endothelial cells lost VE-cadherin
and CD31 expression and acquired α-SMA and vimentin
expression. In addition, VE-cadherin, CD31, and α-SMA
expression was examined by western blot analysis
(Fig. 4c). Consistent with the immunofluorescence re-
sults, western blot analysis revealed that in HKGECs
treated with rMMP-9, levels of the endothelial markers
VE-cadherin and CD31 decreased, whereas the mesen-
chymal marker α-SMA increased (Fig. 4c). Taken to-
gether, these results demonstrate that rMMP-9 induces
EndoMT in HKGECs.
Notch signaling is activated in TGF-β1-induced EndoMT
but is inhibited by MMP-9 inhibitor
To investigate Notch signaling in TGF-β1-induced
EndoMT, we examined the expression of Notch 1 protein
and Notch intracellular domain (NICD) using western
blot analysis. We also evaluated the Notch downstream
transcriptional factors Hes-1 and Hey-1 using qPCR. We
found that when HKGECs were treated with TGF-β1,
Notch-1 expression was significantly down-regulated
whereas NICD was significantly increased compared to
control (Fig. 5a). In addition, when TGF-β1-induced cells
were treated with the MMP-9 inhibitor, NICD expression
decreased (Fig. 5a). The qPCR results showed that TGF-
β1-induced Hes-1 expression in HKGECs was significantly
reduced by MMP-9 inhibitor (Fig. 5b). These results show
that MMP-9 contributes to the Notch pathway activation
in TGF-β1-induced EndoMT.
rMMP-9 activates Notch signaling
We also examined Notch pathway activation in rMMP-
9-induced HKGECs using western blot analysis. After
HKGECs were incubated with rMMP-9, the Notch-1
protein was cleaved and NICD was released (Fig. 6a). To
examine whether rMMP-9 can activate Notch signaling,
different dosages of rMMP-9 (0, 0.25, 0.5, 1.0, 2.0, and
4.0 μg/ml) were added to HKGECs. We found that
Fig. 6 The Notch pathway is activated in rMMP-9-induced EndoMT.
a Respective Western blot analysis and quantitation of Notch-1 and
NICD expression in rMMP-9-induced EndoMT in HKGECs six days
after treatment. b Western blot analysis and quantitation showing
NICD expression is regulated in an rMMP-9 dose-dependent manner.
β-actin was used as a loading control. Data are expressed as mean
± SEM with n ≥ 3 for each experimental group, *P < 0.05, **P < 0.01
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Fig. 7 The γ-secretase inhibitor GSI-I regulates protein expression in rMMP-9-induced EndoMT. a Western blot analysis of α-SMA, NICD, Notch-1,
CD31 and VE-cadherin expression in rMMP-9-induced EndoMT in the presence or absence of GSI-I six days after treatment. β-actin was used as a
loading control. b Statistical analysis of protein expression in rMMP-9-induced EndoMT in the presence or absence of GSI-I. c Morphological
changes in HKGECs induced by TGF-β1 (10 ng/ml) or rMMP-9 in the presence or absence of GSI. Data are expressed as mean ± SEM with n ≥ 3
for each experimental group, *P < 0.05
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NICD level was increased in a rMMP-9 dose-dependent
manner (Fig. 6b).
Inhibition of Notch signaling by γ-secretase inhibitor (GSI)
blocks rMMP-9-induced EndoMT
Notch signaling was inhibited using GSI, an effective γ-
secretase inhibitor (Z-Leu-Leu-Nle-CHO) [29]. Western
blot results (Fig. 7a) and statistical analysis (Fig. 7b)
showed that GSI significantly reduced α-SMA and NICD
expression and increased CD31, VE-cadherin and
Notch-1 expression of cells exposed to MMP-9 com-
pared to cells treated with rMMP-9 alone. GSI inhibited
both TGF-β1- and MMP-9-induced morphological
changes (Fig. 7c). This result demonstrates that the
rMMP-9-induced EndoMT is Notch signaling dependent.
Discussion
Kidney EndoMT is a major source of fibroblast forma-
tion in kidney fibrosis, and has emerged as a potentially
important mechanism in development and progression
of kidney fibrosis [9]. In a recent study, LeBleu et al.
found that endothelial cells play a more important role
than epithelial cells and pericytes in myofibroblast for-
mation via EndoMT [7]. Therefore, understanding and
halting EndoMT is an important clinical challenge.
Kidney endothelial cells consist of glomerular, vascular
and peritubular endothelial cells. Although it has been
generally accepted that endothelial cells contribute to
fibroblast formation in kidney, whether glomerular
endothelial cells contribute to fibroblast formation re-
mains unclear. In our recent study, we showed that mice
peritubular endothelial cells have an important role in
kidney EndoMT. Moreover, we found that MMP-9 was
involved in peritubular EndoMT, likely via the Notch
pathway. Human glomerular endothelial cells are likely
to be another instructive model for studying kidney
fibrosis.
Here, we demonstrate that TGF-β1 and rMMP-9 in-
duced EndoMT in HKGECs via Notch signaling. The
Notch signaling pathway is a highly conserved cascade
in mammals that regulates multiple cellular processes,
including proliferation, differentiation, and apoptosis
[30, 31]. Notch signaling has been shown to be down-
stream of VEGF to regulate endothelial cell morphogen-
esis [32]. In addition, Notch activation induces
endothelial cell morphological, phenotypic, and func-
tional changes consistent with mesenchymal transform-
ation [33]. Notch signaling has been found to initiate
EndoMT in atrioventricular endothelial cells [34]. Inhib-
ition of Notch signaling ameliorates EMT and tubuloin-
terstitial fibrosis in mouse [35]. Importantly, Notch
inhibition reversed podocyte injury (EMT) and kidney
failure [36]. All these findings suggest a critical role for
Notch signaling in both EMT and EndoMT which are
pivotal processes in kidney fibrosis. Our results demon-
strate that MMP-9 activation of Notch signaling in
glomerular endothelial cells is downstream of TGF-β1.
Combining with observations with previous studies from
our laboratory and others, a strong profibrotic role for
MMP-9 is evident. It promotes EMT of tubular epithe-
lial cells, EndoMT of peritubular endothelial cells and
EndoMT of glomerular endothelial cells, thereby, leading
to kidney fibrosis in both tubulointerstial and glomeruli
compartments.
Conclusion
Our data demonstrate that MMP-9 plays an important
role in TGF-β1-induced EndoMT in HKGECs, via up-
regulation of Notch signaling. Thus, inhibition of MMP-
9 or Notch signaling could be therapeutic strategies for
treatment for kidney fibrosis in CKD.
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